MedTrace Logo

Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients

NCT05716477 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 146

Last updated 2025-01-09

No results posted yet for this study

Summary

This clinical trial evaluates the use of a blood test (Guardant Shield™) for colorectal cancer screening. Colorectal cancer is the third leading cancer and cause of death in the United States. Screening may help doctors find colorectal cancer early when it is easier to treat yet nearly a third of all people eligible for screening have never had a screening test performed. Currently, doctors use a stool- based test such as the fecal immunochemical test (FIT) and visual tests such as a colonoscopy. Blood based testing such as Guardant Shield™, may provide a quick and effective way to screen patients that are hard to reach or with limited access (underserved).

Conditions

  • Colorectal Carcinoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Survey Administration

Complete survey

Sponsors & Collaborators

  • Guardant Health, Inc.

    collaborator INDUSTRY

  • Ohio State University Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Electra D Paskett, PhD · Ohio State University Comprehensive Cancer Center

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-23
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05716477 on ClinicalTrials.gov